Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
British Journal of Clinical Pharmacology
|
June 1, 1996
Bioavailability of the antiemetic metopimazine given as a microenema
J Herrstedt, M Jørgensen, H R Angelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J Klastersky, J de Naurois, K Rolston, et al.
Breast Cancer Research and Treatment
|
January 1, 1993
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial
L E Stenbygaard, J Herrstedt, J F Thomsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 10, 2006
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy
J Herrstedt, T C Sigsgaard, H A Nielsen, et al.
British Journal of Cancer
|
July 17, 1999
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
T Sigsgaard, J Herrstedt, L J Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
R de Wit, J Herrstedt, B Rapoport, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2016
Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO
M Klar, A Hasenburg, M Hasanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
J Klastersky, M Paesmans, E B Rubenstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 30, 2004
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
R de Wit, J Herrstedt, B Rapoport, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
British Journal of Clinical Pharmacology
|
June 1, 1996
Bioavailability of the antiemetic metopimazine given as a microenema
J Herrstedt, M Jørgensen, H R Angelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J Klastersky, J de Naurois, K Rolston, et al.
Breast Cancer Research and Treatment
|
January 1, 1993
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial
L E Stenbygaard, J Herrstedt, J F Thomsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 10, 2006
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy
J Herrstedt, T C Sigsgaard, H A Nielsen, et al.
British Journal of Cancer
|
July 17, 1999
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
T Sigsgaard, J Herrstedt, L J Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
R de Wit, J Herrstedt, B Rapoport, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2016
Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO
M Klar, A Hasenburg, M Hasanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
J Klastersky, M Paesmans, E B Rubenstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 30, 2004
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
R de Wit, J Herrstedt, B Rapoport, et al.
Page
of 7